As on Thursday, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) started slowly as it slid -3.05% to $21.65, before settling in for the price of $22.33 at the close. Taking a more long-term approach, ACAD posted a 52-week range of $13.40-$26.65.
Nevertheless, stock’s Earnings Per Share (EPS) this year is -46.11%. This publicly-traded company’s shares outstanding now amounts to $168.71 million, simultaneously with a float of $167.39 million. The organization now has a market capitalization sitting at $3.65 billion. At the time of writing, stock’s 50-day Moving Average stood at $22.70, while the 200-day Moving Average is $20.54.
Acadia Pharmaceuticals Inc (ACAD) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Acadia Pharmaceuticals Inc’s current insider ownership accounts for 0.79%, in contrast to 100.82% institutional ownership. According to the most recent insider trade that took place on Sep 15 ’25, this organization’s EVP, CHIEF FINANCIAL OFFICER sold 3,498 shares at the rate of 23.65, making the entire transaction reach 82,728 in total value, affecting insider ownership by 43,447. Preceding that transaction, on Sep 02 ’25, Company’s Director sold 1,600 for 25.98, making the whole transaction’s value amount to 41,560. This particular insider is now the holder of 25,382 in total.
Acadia Pharmaceuticals Inc (ACAD) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.15 per share during the current fiscal year. Acadia Pharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -46.11% and is forecasted to reach 0.72 in the upcoming year.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Trading Performance Indicators
Let’s observe the current performance indicators for Acadia Pharmaceuticals Inc (ACAD). It’s Quick Ratio in the last reported quarter now stands at 2.94. Alongside those numbers, its PE Ratio stands at $13.94, and its Beta score is 0.68. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.49. Similarly, its price to free cash flow for trailing twelve months is now 19.52.
In the same vein, ACAD’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 1.55, a figure that is expected to reach 0.13 in the next quarter, and analysts are predicting that it will be 0.72 at the market close of one year from today.
Technical Analysis of Acadia Pharmaceuticals Inc (ACAD)
Through scrutinizing the latest numbers posted by the [Acadia Pharmaceuticals Inc, ACAD], it can be observed that its last 5-days Average volume of 1.85 million was lower the volume of 2.16 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 42.77% While, its Average True Range was 44.44.
Raw Stochastic average of Acadia Pharmaceuticals Inc (ACAD) in the period of the previous 100 days is set at 28.16%, which indicates a major fall in contrast to 34.35% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.86 that was higher than 0.78 volatility it exhibited in the past 100-days period.
